Snap a photo of your face and get blood pressure: how a Vietnamese app factory pushed the Nth blood pressure app to #6 in the US

Artera 是越南 iKame(Begamob)在「手机摄像头测血压」这个老品类里开的又一个新牌子。7 月上架后一个多月没动静,10 月 2 日一条 33 秒的视频广告开始在美国投放,安装量就一阶一阶往上跳,10 月底冲到美区 Health & Fitness 免费榜第 6。它跑起来靠的不是产品,是发行商的买量。下面讲它是什么、量从哪来、钱从哪来、用户在骂什么,以及你该不该跟。

One 33-second ad, and one bad review

On YouTube there's a vertical video with only 1 views, from a channel called "App Productivity." The title isn't for humans, it's a creative ID: OSPpsuco55_IABP_..._EN_OS_11_33s_260907. The 260907 at the end is probably when the creative was made, Sep 2026 7 (inferred). The footage shows a middle-aged Black man in glasses and a plaid shirt sitting in a car looking at his phone. Next, an iPhone home screen with a red heart icon labeled "Blood Pressure." Then a wrist raising a phone showing a heart rate reading, with a speech bubble of a woman's avatar reading a "user review":

It measures my blood sugar quickly, without needles, and is free.

This video first appeared in the Google Ads Transparency Center on Oct 2, targeting the US only, and ran through Nov 5 (Google Ads Transparency Center, advertiser BEGAMOB GLOBAL LIMITED, registered in Hong Kong). Note: Artera's own store page doesn't mention blood sugar at all.

Two days later, on Oct 4, a user on Google Play wrote: "The readings are way off from my blood pressure monitor and pulse oximeter. It says my heart rate is 65, when it's actually 108, because I have tachycardia. This is absolutely not a reliable app." Another user wrote on Oct 1: "I downloaded it because it claimed it could check my thyroid. False advertising, it doesn't work at all. Google Play should remove it."

It was during these days that Artera's installs jumped from 20k to 80k.

What it is

A blood pressure / heart rate app. The Google Play store page's first paragraph sells it on "camera measurement technology... no finger scan required." You point the front camera at your face, and it gives you blood pressure, heart rate, a stress index, and a "heart age," plus measurement logs and reminders for medication, water, and sleep.

As usual, the bottom of the store page has a disclaimer: "For general health and fitness purposes only. Not a medical device. Not for diagnosing, treating, monitoring or preventing any disease."

It has an iOS twin (App Store, listed Aug 23), from the same seller, BEGAMOB GLOBAL LIMITED. But the wording differs: the Android listing says "measurement", while the iOS listing swaps everything to "log & track", and it's filed under Lifestyle instead of Health or Medical. A sibling heart-rate app, iCardiac, is even more direct on iOS: "Blood pressure tracking is just a diary feature." This looks like a way to dodge Apple's review.

iKame, the maker, is a tool-app factory in Hanoi. Under the same Google Play developer account there are dozens of apps with over 300M total installs: remote controls, screen casting, PDF, cleaners, translators. The heart rate and blood pressure line alone put out four releases this year: iCardiac in March (finger heart rate, 1.59M installs), FaceVital in June (also "face-scan blood pressure," 143k), Artera in July, and Glucera in August (blood sugar, 50k). Artera is the one picked for extra spending in this round.

Why October: installs were bought in steps

Source: Google Play installs; before Oct 29 figures are third-party estimates.

Organic growth is a smooth curve. Artera is a staircase: every step lines up with a budget increase. Test small, check conversion, then pour money in to push for a category chart. This is the standard playbook of a tool-app factory.

Chart rankings followed the same pattern: US Health & Fitness free chart #29 in October, #30 on 6, #31 on Oct 10, then 21, 34, 44, falling to #6 by November 63. During the same period it briefly charted in Nigeria, the Philippines, South Africa, Argentina, and Mexico (ranked #79–186). It never charted on any grossing chart.

So don't think of it as "a new product taking off." 120k global installs is a rounding error in this category, and its rank is sliding. A more accurate description: one SKU being tested in a big publisher's matrix.

Where users come from

• Google App Ads (confirmed). This is the ad from the opening. The advertiser account has run 1,033 creatives in total, with 200 live in early November, 94% of them app install ads (Google Ads Transparency Center, 11-06). Artera is just one of the landing pages.
• Facebook / Instagram ads (confirmed, scale unknown). The Meta Ad Library shows a page called "Artera: Blood Pressure App Log" running ads with copy like "tracking your heart rate, HRV trends, and daily blood pressure logs takes just seconds on your phone." Clicks go through a redirect at marketing.begamob.com carrying attribution parameters.
• US plus cheap countries (inferred). The US has consistently charted, Nigeria and the Philippines occasionally did, and the most-liked positive review on Play came from a Nigerian user. The typical play is buying paying users in the US and buying cheap installs in lower-cost countries to push charts.
• Keyword stuffing in the title (inferred). The name is "Blood Pressure App Log," so the highest-volume search term goes straight into the title. After breaking into the top ten of a category chart, it picks up a bit of organic traffic from chart placement and search.
• No organic buzz. TikTok search turns up nothing about Artera, nobody mentioned it on X in 60 days, and no media outlet has covered it.

Where the money comes from

On Android it has two monetization paths: in-app purchases, priced on Google Play at $7.99–$49.99, and ads. The store page doesn't label it as ad-supported, but most of the complaints are about ads (see next section). On iOS it's a subscription, reaching as high as #90 on the US Lifestyle grossing chart, and ranking #92–198 on the Lifestyle grossing charts in the Philippines, Indonesia, and several Nordic stores. The iOS version has 545 ratings, with over a hundred added in the last week, suggesting paid acquisition is still running. How much it actually earns is not visible from outside.

Putting the iOS version in Lifestyle also helps (inferred): the Health & Fitness grossing chart is dominated by big fitness apps, while Lifestyle's bar is much lower, so a small app can still crack the grossing chart.

Who's paying? Check the iOS reviews: one user wrote on Sep 23, "Just bought it. It said my blood pressure was 132/77, but when I measured it myself it was 137/55. Not a huge gap, but the second number is the one that matters. I'll try it for a few more days, and if it's still off I'll cancel for a refund." Same day, another user left a one-star review: "All of this is fine, but it's too expensive for seniors living on SSI." That's the buyer: middle-aged and older adults worried about hypertension, with no blood pressure monitor on hand, and price-sensitive.

What users are complaining about

On Google Play, 619 ratings with an average of 4.65. 5-star: 543, which is 88%; 1-star: 29. Ratings from 2 to 4 stars add up to just 35. This "big at both ends, empty in the middle" shape usually means the app is prompting for good reviews (inferred). Reading the reviews, the 5-star ones are mostly "good app", "love it", "nice". The bad ones say three things:

Too many ads to use. "Ads on every few seconds, impossible to use" (10-27); "I couldn't even finish the first scan, I kept closing ads" (11-03); "When I closed an ad the whole app closed too. I restarted it 6 times and never got through setup in 15 minutes" (10-20).

Says free, then asks for money. "Says it's free to download, then the paywall shows up right after setup" (10-03); "Keeps saying free, but you have to pay first. It didn't even scan my face, and it wants me to trust that it works" (11-01); "Stuck on the subscription screen, the continue button won't respond" (9-22).

Inaccurate readings, unclear explanations. The user with tachycardia from the opening; another asked, "Normal blood pressure is 120/80, mine is 116/76, it says I'm in the elevated range, why?" (10-16).

Some say it's accurate: "Just back from the doctor, this report matches what the doctor said pretty closely" (10-30). Harvard Health and Scientific American have both published warnings against trusting face-based blood pressure readings, and the US Federal Trade Commission has previously penalized apps that claimed to measure blood pressure with a phone.

Who it's competing with

This category is crowded. Almost all of it is run by tool-app factories, and Artera is a small player among them (installs are from Google Play, 11-06):

Face-scan measurement wasn't invented here either: Shen.AI is a technology vendor for face-based heart rate and blood pressure measurement, with an SDK and clinical data; NuraLogix's Anura has been doing "30-second selfie blood pressure" for several years, on the research-paper and medical-device path. Big companies sit above them too: Apple Watch hypertension notifications, blood pressure trends on Pixel Watch launched in September 24, and blood pressure features on Samsung watches. Those require you to buy a watch and only give you trends and alerts. Artera-style apps sell "no watch, no cost, measure right now."

Same hook: FaceVital, a sibling, only reached 140k, while BearKUN, launched the same month, reached 2.97M. The difference isn't features, it's who bought more and whose creatives converted better.

What to learn from it

• One category split into several brands by selling point. Finger measurement, face measurement, and blood sugar each get a package. Test small paid installs to check conversion, then push money into whichever one works to chase a category chart.
• On iOS, change the wording and the category. "Measure" becomes "log & track," and the category is Lifestyle. That dodges review and gets into the grossing chart, which has a lower bar.
• The ad hook is "one scan, instant numbers." A video showing a reading right after a scan sells much better than "a logging app." But its creatives already hint at blood sugar and thyroid, which is where the one-star reviews and takedown risk come from.

If it were you

In short: Learn from it, but don't follow it. This is a business of who buys more and whose creatives dare to make bigger claims. The category is already saturated, and Artera itself has only 120k installs with its rank falling.

Who it suits: studios that already run a matrix of tool apps, have Google UAC accounts and a creative team ready, and can run several packages at once. For them it's just another SKU to test.

Who it doesn't suit: indie developers and small teams without a paid acquisition budget. There's no organic traffic here. Artera has nothing on TikTok, X, or in the media, so all its volume is bought. Top apps add hundreds of thousands of new users a week, and your budget won't last long enough to get noticed. It's also a poor fit for anyone who cares about accuracy: phone-based blood pressure measurement isn't reliable, and once users compare against a real cuff, it's a one-star review.

How to do it (if you must): Don't build "face-scan blood pressure." Build the part nobody does well. The most common complaints are too many ads and charging after saying free. A clean blood pressure log built for older users: large text, connects to a Bluetooth BP cuff, exports a report you can show your doctor, and a one-time purchase or a cheap annual plan. This route doesn't depend on "measurement," so it avoids medical claims. But note that the market leader, Blood Pressure Tracker, is also manual logging, with 97.3M installs.

How to get users: Follow where the need is: hypertension and diabetes support groups on Facebook, and groups of adult children caring for aging parents. Make creatives about "turn a month of blood pressure readings into a table for your doctor," not "one scan, instant readings."

When to worry: No rush. This category is evergreen, there's no window. The real time pressure is policy: the day Google Play tightens rules on misleading health claims, the apps that grew by "testing" go down first.

What would show I'm reading this wrong: ① Artera climbs back into the US store's category chart top 10 in November and charts Top Grossing on Android too. That would mean the "face scan" hook converts well enough to earn steadily, and it's worth a second look. ② Within two or three months, a small team with no publisher backing hits a million installs on a blood pressure app without relying on paid acquisition. ③ The reverse: Google Play or the App Store pulls a wave of "camera blood pressure" apps. Then don't build it, not even as a factory play.

---

Data and sources: Google Play store pages, install counts and charts (installs before 2026-11-06,10-29 are third-party estimates); Google Play and App Store user reviews (September–November); Google Ads Transparency Center, advertiser BEGAMOB GLOBAL LIMITED and its video creatives (YouTube wHYM3jA_9tA, screenshot 11-06); Meta Ad Library, Library ID 1120529477144167; App Store pages and ratings; Google Health blog (2026-09-24); Harvard Health and Scientific American articles on phone blood pressure measurement; iKame's website and public case studies. Anything marked "inferred" or "estimated" is an inference or estimate.